|
 |
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 47, 15-31, January 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology
Thematic Review |
Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors
Schering-Plough Research Institute, Kenilworth, NJ 07033
Published, JLR Papers in Press, November 8, 2005.
1 To whom correspondence should be addressed. e-mail: andrea.basso{at}spcorp.com
Some proteins undergo posttranslational modification by the addition of an isoprenyl lipid (farnesyl- or geranylgeranyl-isoprenoid) to a cysteine residue proximal to the C terminus. Protein isoprenylation promotes membrane association and contributes to protein-protein interactions. Farnesylated proteins include small GTPases, tyrosine phosphatases, nuclear lamina, cochaperones, and centromere-associated proteins. Prenylation is required for the transforming activity of Ras. Because of the high frequency of Ras mutations in cancer, farnesyl transferase inhibitors (FTIs) were investigated as a means to antagonize Ras function. Evaluation of FTIs led to the finding that both K- and N-Ras are alternatively modified by geranylgeranyl prenyltransferase-1 in FTI-treated cells. Geranylgeranylated forms of Ras retain the ability to associate with the plasma membrane and activate substrates. Despite this, FTIs are effective at inhibiting the growth of human tumor cells in vitro, suggesting that activity is dependent on blocking the farnesylation of other proteins. FTIs also inhibit the in vivo growth of human tumor xenografts and sensitize these models to chemotherapeutics, most notably taxanes. Several FTIs have entered clinical trials for various cancer indications. In some clinical settings, primarily hematologic malignancies, FTIs have displayed evidence of single-agent activity. Clinical studies in progress are exploring the antitumor activity of FTIs as single agents and in combination. This review will summarize the basic biology of FTIs, their antitumor activity in preclinical models, and the current status of clinical studies with these agents.
Supplementary key words Ionafarnib • tipifarnib • BMS-214662 • L-778123 • Ras • Rheb • HDJ • Iamin • RhoB • CENP
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Hast and L. S. Beese Structure of Protein Geranylgeranyltransferase-I from the Human Pathogen Candida albicans Complexed with a Lipid Substrate J. Biol. Chem., November 14, 2008; 283(46): 31933 - 31940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. C. Capell, M. Olive, M. R. Erdos, K. Cao, D. A. Faddah, U. L. Tavarez, K. N. Conneely, X. Qu, H. San, S. K. Ganesh, et al. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model PNAS, October 14, 2008; 105(41): 15902 - 15907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eisenberg, K. Giehl, Y. I. Henis, and M. Ehrlich Differential Interference of Chlorpromazine with the Membrane Interactions of Oncogenic K-Ras and Its Effects on Cell Growth J. Biol. Chem., October 3, 2008; 283(40): 27279 - 27288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Jackson and T. A. Kocarek Suppression of CYP2B Induction by Alendronate-Mediated Farnesyl Diphosphate Synthase Inhibition in Primary Cultured Rat Hepatocytes Drug Metab. Dispos., October 1, 2008; 36(10): 2030 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Wojtkowiak, F. Fouad, D. T. LaLonde, M. D. Kleinman, R. A. Gibbs, J. J. Reiners Jr., R. F. Borch, and R. R. Mattingly Induction of Apoptosis in Neurofibromatosis Type 1 Malignant Peripheral Nerve Sheath Tumor Cell Lines by a Combination of Novel Farnesyl Transferase Inhibitors and Lovastatin J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. H. van der Hilst, B. Kluve-Beckerman, E. J. Bodar, J. W. M. van der Meer, J. P. H. Drenth, and A. Simon Lovastatin inhibits formation of AA amyloid J. Leukoc. Biol., May 1, 2008; 83(5): 1295 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shutes, C. Onesto, V. Picard, B. Leblond, F. Schweighoffer, and C. J. Der Specificity and Mechanism of Action of EHT 1864, a Novel Small Molecule Inhibitor of Rac Family Small GTPases J. Biol. Chem., December 7, 2007; 282(49): 35666 - 35678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Van Voorhis, K. L. Rivas, P. Bendale, L. Nallan, C. Horney, L. K. Barrett, K. D. Bauer, B. P. Smart, S. Ankala, O. Hucke, et al. Efficacy, Pharmacokinetics, and Metabolism of Tetrahydroquinoline Inhibitors of Plasmodium falciparum Protein Farnesyltransferase Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3659 - 3671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Raz, V. Nardi, M. Azam, J. Cortes, and G. Q. Daley Farnesyl transferase inhibitor resistance probed by target mutagenesis Blood, September 15, 2007; 110(6): 2102 - 2109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Zheng, J. McKay, and J. E. Buss H-Ras Does Not Need COP I- or COP II-dependent Vesicular Transport to Reach the Plasma Membrane J. Biol. Chem., August 31, 2007; 282(35): 25760 - 25768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Qiu, X. Liu, W. Zou, P. Yue, S. Lonial, F. R. Khuri, and S.-Y. Sun The Farnesyltransferase Inhibitor R115777 Up-regulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells Cancer Res., May 15, 2007; 67(10): 4973 - 4980. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Grabinska, P. Magnelli, and P. W. Robbins Prenylation of Saccharomyces cerevisiae Chs4p Affects Chitin Synthase III Activity and Chitin Chain Length Eukaryot. Cell, February 1, 2007; 6(2): 328 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Navarro, P. Cau, and N. Levy Molecular bases of progeroid syndromes Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R151 - R161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Rusinol and M. S. Sinensky Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors. J. Cell Sci., August 15, 2006; 119(Pt 16): 3265 - 3272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Kavanagh, J. E. Dunford, G. Bunkoczi, R. G. G. Russell, and U. Oppermann The Crystal Structure of Human Geranylgeranyl Pyrophosphate Synthase Reveals a Novel Hexameric Arrangement and Inhibitory Product Binding J. Biol. Chem., August 4, 2006; 281(31): 22004 - 22012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Mitchell, A. Vasudevan, M. E. Linder, and R. J. Deschenes Thematic review series: Lipid Posttranslational Modifications. Protein palmitoylation by a family of DHHC protein S-acyltransferases J. Lipid Res., June 1, 2006; 47(6): 1118 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Wright and M. R. Philips Thematic review series: Lipid Posttranslational Modifications CAAX modification and membrane targeting of Ras J. Lipid Res., May 1, 2006; 47(5): 883 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Lane and L. S. Beese Thematic review series: Lipid Posttranslational Modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I J. Lipid Res., April 1, 2006; 47(4): 681 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Leung, R. Baron, and M. C. Seabra Thematic review series: Lipid Posttranslational Modifications. Geranylgeranylation of Rab GTPases J. Lipid Res., March 1, 2006; 47(3): 467 - 475. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |